Insmed AstraZeneca milestone — Intangible Amortization increased by 244.8% to $818.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 244.8%, from $237.25K to $818.00K. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase reflects a larger base of amortizable assets, which reduces reported net income without impacting cash flow.
This represents the periodic non-cash expense recognized to allocate the cost of intangible assets acquired through Astr...
Comparable to amortization of acquired IPR&D or intangible assets reported by peers following the commercialization or regulatory approval of licensed products.
insm_segment_astrazeneca_milestone_amortization_of_intangible_assets| Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $237.25K | $237.25K | $237.25K | $237.25K | $818.00K |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +244.8% |
| YoY Change | — | — | — | — | +244.8% |